2024
Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment
Wang J, Huang Q, He K, Li J, Guo T, Yang Y, Lin Z, Li S, Vanderlinden G, Huang Y, Van Laere K, Guan Y, Guo Q, Ni R, Li B, Xie F. Presynaptic density determined by SV2A PET is closely associated with postsynaptic metabotropic glutamate receptor 5 availability and independent of amyloid pathology in early cognitive impairment. Alzheimer's & Dementia 2024, 20: 3876-3888. PMID: 38634334, PMCID: PMC11180932, DOI: 10.1002/alz.13817.Peer-Reviewed Original ResearchMGluR5 availabilityMedial temporal lobeSynaptic densityTemporal lobeHealthy controlsAlzheimer's diseaseMetabotropic glutamate receptor 5Glutamate receptor 5Synaptic lossIntegrative brain functionsCognitively impaired patientsEarly cognitive impairmentGlobal cognitionMGluR5 signalingMediation analysisPathophysiological mechanism of Alzheimer's diseaseBrain functionCognitive impairmentMGluR5CognitionImproving synaptic functionImpaired patientsSynaptic functionSynaptic transmissionAmyloid pathology
2004
Screening and Cognitive Impairment: Ethics of Forgoing Mammography in Older Women
Raik B, Miller F, Fins J. Screening and Cognitive Impairment: Ethics of Forgoing Mammography in Older Women. Journal Of The American Geriatrics Society 2004, 52: 440-444. PMID: 14962162, DOI: 10.1111/j.1532-5415.2004.52119.x.Peer-Reviewed Original ResearchConceptsCognitively impaired womenCognitive impairmentQuality of lifeDecision-making capacityScreening interventionsMammographic screeningEarly cognitive impairmentLonger life expectancyPatient's capacityVulnerable populationsImpaired womenLife expectancyRisk of undertreatmentMammographyBreast cancerWomenEthical questionsDecision-making processPotential benefitsRiskScreeningRisk/benefit analysisImpairmentOlderDementia
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply